{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:24:55Z","timestamp":1771053895129,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Robert Bosch Center for Data Science and Artificial Inelligence (RBCDSAI), Indian Institute of Technology Madras","award":["SB\/20-21\/0601\/BT\/RBCX\/008473"],"award-info":[{"award-number":["SB\/20-21\/0601\/BT\/RBCX\/008473"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The urgent need for a treatment of COVID-19 has left researchers with limited choice of either developing an effective vaccine or identifying approved\/investigational drugs developed for other medical conditions for potential repurposing, thus bypassing long clinical trials. In this work, we compared the sequences of experimentally verified SARS-CoV-2 neutralizing antibodies and sequentially\/structurally similar commercialized therapeutic monoclonal antibodies. We have identified three therapeutic antibodies, Tremelimumab, Ipilimumab and Afasevikumab. Interestingly, these antibodies target CTLA4 and IL17A, levels of which have been shown to be elevated during severe SARS-CoV-2 infection. The candidate antibodies were evaluated further for epitope restriction, interaction energy and interaction surface to gauge their repurposability to tackle SARS-CoV-2 infection. Our work provides candidate antibody scaffolds with dual activities of plausible viral neutralization and immunosuppression. Further, these candidate antibodies can also be explored in diagnostic test kits for SARS-CoV-2 infection. We opine that this in silico workflow to screen and analyze antibodies for repurposing would have widespread applications.<\/jats:p>","DOI":"10.1038\/s41598-021-89621-6","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T10:04:23Z","timestamp":1620900263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies"],"prefix":"10.1038","volume":"11","author":[{"given":"Puneet","family":"Rawat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambuj","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vani","family":"Janakiraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Michael","family":"Gromiha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"89621_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"89621_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395, 565\u2013574 (2020).","journal-title":"Lancet"},{"key":"89621_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/22221751.2020.1725399","volume":"9","author":"L Chen","year":"2020","unstructured":"Chen, L. et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg. Microbes Infect. 9, 313\u2013319 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"89621_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01516-2","author":"D Yesudhas","year":"2020","unstructured":"Yesudhas, D., Srivastava, A. & Gromiha, M. M. COVID-19 outbreak: History, mechanism, transmission, structural studies and therapeutics. Infection https:\/\/doi.org\/10.1007\/s15010-020-01516-2 (2020).","journal-title":"Infection"},{"key":"89621_CR5","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.2174\/1568026620666200710105507","volume":"20","author":"A Shanmugam","year":"2020","unstructured":"Shanmugam, A., Muralidharan, N., Velmurugan, D. & Gromiha, M. M. Therapeutic targets and computational approaches on drug development for COVID-19. Curr. Top. Med. Chem. 20, 2210\u20132220 (2020).","journal-title":"Curr. Top. Med. Chem."},{"key":"89621_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221\u2013224 (2020).","journal-title":"Nature"},{"key":"89621_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","volume":"7","author":"L Du","year":"2009","unstructured":"Du, L. et al. The spike protein of SARS-CoV\u2014a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226\u2013236 (2009).","journal-title":"Nat. Rev. Microbiol."},{"key":"89621_CR8","doi-asserted-by":"publisher","first-page":"117883","DOI":"10.1016\/j.lfs.2020.117883","volume":"256","author":"A Pandey","year":"2020","unstructured":"Pandey, A. et al. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. Life Sci. 256, 117883 (2020).","journal-title":"Life Sci."},{"key":"89621_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12967-020-02392-y","volume":"18","author":"G Salvatori","year":"2020","unstructured":"Salvatori, G. et al. SARS-CoV-2 SPIKE PROTEIN: An optimal immunological target for vaccines. J. Transl. Med. 18, 222 (2020).","journal-title":"J. Transl. Med."},{"key":"89621_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1820482","author":"S Jiang","year":"2020","unstructured":"Jiang, S., Zhang, X. & Du, L. Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2. Expert Opin. Ther. https:\/\/doi.org\/10.1080\/14728222.2020.1820482 (2020).","journal-title":"Expert Opin. Ther."},{"key":"89621_CR11","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"L Caly","year":"2020","unstructured":"Caly, L., Druce, J. D., Catton, M. G., Jans, D. A. & Wagstaff, K. M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 178, 104787 (2020).","journal-title":"Antiviral Res."},{"key":"89621_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1752802","author":"N Muralidharan","year":"2020","unstructured":"Muralidharan, N., Sakthivel, R., Velmurugan, D. & Gromiha, M. M. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19. J. Biomol. Struct. Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1752802 (2020).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"89621_CR13","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"LW Madsen","year":"2020","unstructured":"Madsen, L. W. Remdesivir for the treatment of Covid-19-final report. N. Engl. J. Med. 383, 1813\u20131826 (2020).","journal-title":"N. Engl. J. Med."},{"key":"89621_CR14","first-page":"215","volume":"49","author":"J Chen","year":"2020","unstructured":"Chen, J. et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban 49, 215\u2013219 (2020).","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"89621_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","volume":"586","author":"L Riva","year":"2020","unstructured":"Riva, L. et al. Discovery of SARS-CoV-2 anti-viral drugs through large-scale compound repurposing. Nature 586, 113\u2013119 (2020).","journal-title":"Nature"},{"key":"89621_CR16","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3389\/fimmu.2020.01664","volume":"11","author":"S Choudhary","year":"2020","unstructured":"Choudhary, S., Malik, Y. S. & Tomar, S. Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach. Front. Immunol. 11, 1664 (2020).","journal-title":"Front. Immunol."},{"key":"89621_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","volume":"6","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2. Cell Discov. 6, 14 (2020).","journal-title":"Cell Discov."},{"key":"89621_CR18","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1038\/s41467-020-17189-2","volume":"11","author":"S Sadegh","year":"2020","unstructured":"Sadegh, S. et al. Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing. Nat. Commun. 11, 3518 (2020).","journal-title":"Nat. Commun."},{"key":"89621_CR19","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jama.2021.1225","volume":"325","author":"EC Lloyd","year":"2021","unstructured":"Lloyd, E. C., Gandhi, T. N. & Petty, L. A. Monoclonal antibodies for COVID-19. JAMA 325, 1015 (2021).","journal-title":"JAMA"},{"key":"89621_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"P Brouwer","year":"2020","unstructured":"Brouwer, P. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643\u2013650 (2020).","journal-title":"Science"},{"key":"89621_CR21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1126\/science.abc7424","volume":"369","author":"AZ Wec","year":"2020","unstructured":"Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 369, 731\u2013736 (2020).","journal-title":"Science"},{"key":"89621_CR22","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024\u20131042 (2020).","journal-title":"Cell"},{"key":"89621_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btaa739","author":"MI Raybould","year":"2020","unstructured":"Raybould, M. I., Kovaltsuk, A., Marks, C. & Deane, C. M. CoV-AbDab: The coronavirus antibody database. Bioinformatics https:\/\/doi.org\/10.1093\/bioinformatics\/btaa739 (2020).","journal-title":"Bioinformatics"},{"key":"89621_CR24","doi-asserted-by":"publisher","first-page":"D383","DOI":"10.1093\/nar\/gkz827","volume":"48","author":"MI Raybould","year":"2020","unstructured":"Raybould, M. I. et al. Thera-SAbDab: The therapeutic structural antibody database. Nucleic Acids Res. 48, D383\u2013D388 (2020).","journal-title":"Nucleic Acids Res."},{"key":"89621_CR25","doi-asserted-by":"publisher","first-page":"D464","DOI":"10.1093\/nar\/gky1004","volume":"47","author":"SK Burley","year":"2019","unstructured":"Burley, S. K. et al. RCSB Protein Data Bank: Biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy. Nucleic Acids Res. 47, D464\u2013D474 (2019).","journal-title":"Nucleic Acids Res."},{"key":"89621_CR26","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/s41423-020-00523-5","volume":"17","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell. Mol. Immunol. 17, 1095\u20131097 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"89621_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"89621_CR28","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1093\/bioinformatics\/btp163","volume":"25","author":"PJ Cock","year":"2009","unstructured":"Cock, P. J. et al. Biopython: Freely available Python tools for computational molecular biology and bioinformatics. Bioinformatics 25, 1422\u20131423 (2009).","journal-title":"Bioinformatics"},{"key":"89621_CR29","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/bioinformatics\/btv552","volume":"32","author":"J Dunbar","year":"2016","unstructured":"Dunbar, J. & Deane, C. M. ANARCI: Antigen receptor numbering and receptor classification. Bioinformatics 32, 298\u2013300 (2016).","journal-title":"Bioinformatics"},{"key":"89621_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0145-305X(02)00039-3","volume":"27","author":"MP Lefranc","year":"2003","unstructured":"Lefranc, M. P. et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev. Comp. Immunol. 27, 55\u201377 (2003).","journal-title":"Dev. Comp. Immunol."},{"key":"89621_CR31","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/bioinformatics\/btp033","volume":"25","author":"AM Waterhouse","year":"2009","unstructured":"Waterhouse, A. M., Procter, J. B., Martin, D. M., Clamp, M. & Barton, G. J. Jalview Version 2\u2014a multiple sequence alignment editor and analysis workbench. Bioinformatics 25, 1189\u20131191 (2009).","journal-title":"Bioinformatics"},{"key":"89621_CR32","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/molbev\/mst010","volume":"30","author":"K Katoh","year":"2013","unstructured":"Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: Improvements in performance and usability. Mol. Biol. Evol. 30, 772\u2013780 (2013).","journal-title":"Mol. Biol. Evol."},{"key":"89621_CR33","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1080\/19420862.2016.1205773","volume":"8","author":"J Leem","year":"2016","unstructured":"Leem, J., Dunbar, J., Georges, G., Shi, J. & Deane, C. M. ABodyBuilder: Automated antibody structure prediction with data\u2013driven accuracy estimation. MAbs 8, 1259\u20131268 (2016).","journal-title":"MAbs"},{"key":"89621_CR34","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/bioinformatics\/btu190","volume":"30","author":"K Krawczyk","year":"2014","unstructured":"Krawczyk, K., Liu, X., Baker, T., Shi, J. & Deane, C. M. Improving B-cell epitope prediction and its application to global antibody-antigen docking. Bioinformatics 30, 2288\u20132294 (2014).","journal-title":"Bioinformatics"},{"key":"89621_CR35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/prot.25219","volume":"85","author":"S Vajda","year":"2017","unstructured":"Vajda, S. et al. New additions to the Clus Pro server motivated by CAPRI. Proteins 85, 435\u2013444 (2017).","journal-title":"Proteins"},{"key":"89621_CR36","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1093\/bioinformatics\/btz184","volume":"35","author":"J Delgado","year":"2019","unstructured":"Delgado, J., Radusky, L. G., Cianferoni, D. & Serrano, L. FoldX 5.0: Working with RNA, small molecules and a new graphical interface. Bioinformatics 35, 4168\u20134169 (2019).","journal-title":"Bioinformatics"},{"key":"89621_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/prot.340160102","volume":"16","author":"TT Wu","year":"1993","unstructured":"Wu, T. T., Johnson, G. & Kabat, E. A. Length distribution of CDRH3 in antibodies. Proteins 16, 1\u20137 (1993).","journal-title":"Proteins"},{"key":"89621_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1074-7613(00)00006-6","volume":"13","author":"JL Xu","year":"2000","unstructured":"Xu, J. L. & Davis, M. M. Diversity in the CDR3 region of VH is sufficient for most antibody specificities. Immunity 13, 37\u201345 (2000).","journal-title":"Immunity"},{"key":"89621_CR39","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1006\/cyto.1998.0433","volume":"11","author":"HCK Shin","year":"1999","unstructured":"Shin, H. C. K., Benbernou, N., Esnault, S. & Guenounou, M. Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway. Cytokine 11, 257\u2013266 (1999).","journal-title":"Cytokine"},{"key":"89621_CR40","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1053\/j.seminoncol.2010.09.010","volume":"37","author":"A Ribas","year":"2010","unstructured":"Ribas, A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin. Oncol. 37, 450\u2013454 (2010).","journal-title":"Semin. Oncol."},{"key":"89621_CR41","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","volume":"17","author":"HY Zheng","year":"2020","unstructured":"Zheng, H. Y. et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell. Mol. Immunol. 17, 541\u2013543 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"89621_CR42","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00134-020-06127-x","volume":"46","author":"R Jeannet","year":"2020","unstructured":"Jeannet, R., Daix, T., Formento, R., Feuillard, J. & Fran\u00e7ois, B. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression. Intensive Care Med. 46, 1769\u20131771 (2020).","journal-title":"Intensive Care Med."},{"key":"89621_CR43","doi-asserted-by":"publisher","first-page":"eabd7114","DOI":"10.1126\/sciimmunol.abd7114","volume":"5","author":"L Kuri-Cervantes","year":"2020","unstructured":"Kuri-Cervantes, L. et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci. Immunol. 5, eabd7114 (2020).","journal-title":"Sci. Immunol."},{"key":"89621_CR44","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41577-020-0402-6","volume":"20","author":"Z Chen","year":"2020","unstructured":"Chen, Z. & Wherry, E. J. T cell responses in patients with COVID-19. Nat. Rev. Immunol. 20, 529\u2013536 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"89621_CR45","doi-asserted-by":"publisher","first-page":"e142167","DOI":"10.1172\/jci.insight.142167","volume":"5","author":"D Schub","year":"2020","unstructured":"Schub, D. et al. High levels of SARS-CoV-2\u2013specific T cells with restricted functionality in severe courses of COVID-19. JCI insight 5, e142167 (2020).","journal-title":"JCI insight"},{"key":"89621_CR46","doi-asserted-by":"publisher","first-page":"2002182","DOI":"10.1183\/13993003.02182-2020","volume":"56","author":"E Stephen-Victor","year":"2020","unstructured":"Stephen-Victor, E. et al. Potential of regulatory T-cell-based therapies in the management of severe COVID-19. Eur. Respir. J. 56, 2002182 (2020).","journal-title":"Eur. Respir. J."},{"key":"89621_CR47","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41577-020-0328-z","volume":"20","author":"O Pacha","year":"2020","unstructured":"Pacha, O., Sallman, M. A. & Evans, S. E. COVID-19: A case for inhibiting IL-17?. Nat. Rev. Immunol. 20, 345\u2013346 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"89621_CR48","doi-asserted-by":"publisher","first-page":"109749","DOI":"10.1016\/j.mehy.2020.109749","volume":"140","author":"M Megna","year":"2020","unstructured":"Megna, M., Napolitano, M. & Fabbrocini, G. May IL-17 have a role in COVID-19 infection?. Med. Hypotheses 140, 109749 (2020).","journal-title":"Med. Hypotheses"},{"key":"89621_CR49","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/jmv.25801","volume":"92","author":"P Luo","year":"2020","unstructured":"Luo, P. et al. Tocilizumab treatment in COVID-19: A single center experience. J. Med. Virol. 92, 814\u2013818 (2020).","journal-title":"J. Med. Virol."},{"key":"89621_CR50","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaci.2020.05.008","volume":"146","author":"T Herold","year":"2020","unstructured":"Herold, T. et al. Elevated levels of interleukin-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 146, 128\u2013136 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"89621_CR51","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molimm.2012.06.001","volume":"53","author":"JV Kringelum","year":"2013","unstructured":"Kringelum, J. V., Nielsen, M., Padkj\u00e6r, S. B. & Lund, O. Structural analysis of B-cell epitopes in antibody: Protein complexes. Mol. Immunol. 53, 24\u201334 (2013).","journal-title":"Mol. Immunol."},{"key":"89621_CR52","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-020-0732-3","volume":"15","author":"HF Florindo","year":"2020","unstructured":"Florindo, H. F. et al. Immune-mediated approaches against COVID-19. Nat. Nanotechnol. 15, 630\u2013645 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"89621_CR53","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(20)30920-X","volume":"395","author":"H Li","year":"2020","unstructured":"Li, H. et al. SARS-CoV-2 and viral sepsis: Observations and hypotheses. Lancet 395, 1517\u20131520 (2020).","journal-title":"Lancet"},{"key":"89621_CR54","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1634\/theoncologist.2012-0483","volume":"18","author":"LA Fecher","year":"2013","unstructured":"Fecher, L. A., Agarwala, S. S., Hodi, F. S. & Weber, J. S. Ipilimumab and its toxicities: A multidisciplinary approach. Oncologist 18, 733 (2013).","journal-title":"Oncologist"},{"key":"89621_CR55","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000464285","volume":"6","author":"EH Gan","year":"2017","unstructured":"Gan, E. H., Mitchell, A. L., Plummer, R., Pearce, S. & Perros, P. Tremelimumab-induced graves hyperthyroidism. Eur. Thyroid J. 6, 167\u2013170 (2017).","journal-title":"Tremelimumab-induced graves hyperthyroidism. Eur. Thyroid J."},{"key":"89621_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-018-0280-z","volume":"21","author":"K Peng","year":"2019","unstructured":"Peng, K. et al. Measurement of IL-17AA and IL-17FF as pharmacodynamic biomarkers to demonstrate target engagement in the phase I study of MCAF5352A. AAPS J. 21, 1\u20139 (2019).","journal-title":"AAPS J."},{"key":"89621_CR57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ymeth.2017.09.008","volume":"131","author":"A Roy","year":"2017","unstructured":"Roy, A., Nair, S., Sen, N., Soni, N. & Madhusudhan, M. S. In silico methods for design of biological therapeutics. Methods 131, 33\u201365 (2017).","journal-title":"Methods"},{"key":"89621_CR58","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1093\/bib\/bbz095","volume":"21","author":"RA Norman","year":"2020","unstructured":"Norman, R. A. et al. Computational approaches to therapeutic antibody design: Established methods and emerging trends. Brief. Bioinform. 21, 1549\u20131567 (2020).","journal-title":"Brief. Bioinform."},{"key":"89621_CR59","doi-asserted-by":"publisher","first-page":"9781","DOI":"10.1021\/acs.jpclett.0c02706","volume":"11","author":"B Luan","year":"2020","unstructured":"Luan, B. & Huynh, T. In silico antibody mutagenesis for optimizing its binding to spike protein of severe acute respiratory syndrome coronavirus 2. J. Phys. Chem. Lett. 11, 9781\u20139787 (2020).","journal-title":"J. Phys. Chem. Lett."},{"key":"89621_CR60","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.03.024885","author":"T Desautels","year":"2020","unstructured":"Desautels, T., Zemla, A., Lau, E., Franco, M. & Faissol, D. Rapid in silico design of antibodies targeting SARS-CoV-2 using machine learning and supercomputing. BioRxiv https:\/\/doi.org\/10.1101\/2020.04.03.024885 (2020).","journal-title":"BioRxiv"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89621-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89621-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89621-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T17:57:23Z","timestamp":1699034243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89621-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["89621"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-89621-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,13]]},"assertion":[{"value":"6 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10220"}}